|Bid||2.8000 x 3100|
|Ask||2.8100 x 2900|
|Day's range||2.5700 - 2.9100|
|52-week range||2.1500 - 13.6800|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.50|
SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on Thursday, May 26, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress. The webcast can be accessed on the day
Investing in stocks comes with the risk that the share price will fall. And unfortunately for 23andMe Holding Co...
In this podcast, Motley Fool contributor Brian Orelli interviews Anne Wojcicki, the CEO of 23andMe (NASDAQ: ME), about her company and why it's looking to tell you much more than the names of your long-lost relatives. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Anne Wojcicki: [MUSIC] When I think one of our legacies, hopefully, will be, is that 23andme has really proven that complicated information can go direct to a consumer, it does not have to have a one-to-one interaction with the physician.